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Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide.
Comprehensive genomic characterization of ESCC will further our understanding of the
carcinogenesis process in this disease.
Results: Genome-wide detection of chromosomal changes was performed using the Affymetrix
GeneChip 10 K single nucleotide polymorphism (SNP) array, including loss of heterozygosity
(LOH) and copy number alterations (CNA), for 26 pairs of matched germ-line and micro-dissected
tumor DNA samples. LOH regions were identified by two methods – using Affymetrix's genotype
call software and using Affymetrix's copy number alteration tool (CNAT) software – and both
approaches yielded similar results. Non-random LOH regions were found on 10 chromosomal
arms (in decreasing order of frequency: 17p, 9p, 9q, 13q, 17q, 4q, 4p, 3p, 15q, and 5q), including 20
novel LOH regions (10 kb to 4.26 Mb). Fifteen CNA-loss regions (200 kb to 4.3 Mb) and 36 CNA-
gain regions (200 kb to 9.3 Mb) were also identified.
Conclusion: These studies demonstrate that the Affymetrix 10 K SNP chip is a valid platform to
integrate analyses of LOH and CNA. The comprehensive knowledge gained from this analysis will
enable improved strategies to prevent, diagnose, and treat ESCC.
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Background
Genetic instabilities are characteristic of most human can-
cers. Genome-wide detection of chromosomal changes,
including loss of heterozygosity (LOH) and copy number
alterations (CNA), either gain or loss, are the focus of sub-
stantial attention in cancer research. LOH is frequently
observed in a variety of human cancers, and regions with
frequent LOH may contain tumor suppressor genes. In
addition, LOH may associate with the regions affected by
haplo-insufficiency of a group of genes. Thus, detection of
LOH will likely remain a cornerstone for predicting tumor
aggressiveness for many human tumors [1]. Recently, the
discovery of large-scale genome-wide copy number varia-
tion has stimulated interest in elucidating the role of CNA
in the development of malignancy. The 10 K single nucle-
otide polymorphism (SNP) array (GeneChip Mapping 10
K array, Affymetrix) offers a high-resolution genomic
approach to screen chromosomal alterations systemati-
cally. Several studies on allelic imbalance or loss in can-
cers and cancer cell lines using the 10 K SNP array have
been published [2-12].
Esophageal squamous cell carcinoma (ESCC) is a com-
mon malignancy worldwide and one of the most com-
mon malignancies in the Chinese population. There is
great geographic variation in the occurrence of this tumor
in China, including exceptionally high-risk areas such as
Shanxi Province in north central China where some of the
highest esophageal cancer rates in the world occur. The
standardized incidence rate for esophageal cancer in
Shanxi Province is above 100/100,000 person-years,
although it appears that both incidence and mortality
rates have begun to decline in the past 10 years [13,14].
Within the high-risk regions in China, there is a strong
tendency toward familial aggregation, suggesting that
genetic susceptibility, in conjunction with environmental
exposures, plays a role in the etiology of ESCC. In the past
several years, we have tried to identify susceptibility genes
and biomarkers that can be used to screen high-risk pop-
ulations in north central China for ESCC [15-22]. A previ-
ous study examined 366 microsatellite markers in a 10 cM
density genome-wide scan in 11 ESCC patients, and iden-
tified 14 chromosome arms with high-frequency LOH
[15]. However, we were unable to further narrow these
LOH regions using microsatellite markers due to their low
density. Higher density markers are necessary for posi-
tional cloning of tumor suppressor genes in LOH regions.
In the present study we established a high-resolution
chromosomal instability profile for ESCC by examining
germ-line DNA and matched micro-dissected tumor DNA
with a 10 K SNP array to determine both LOH and CNA.
We also evaluated whether a pool of normal control sam-
ples could be used as the normal referent in an LOH study
with the 10 K SNP chip instead of matched germ-line
DNA.
Results and discussion
LOH by patient and chromosomal arms
In the present study, 26 ESCC patients with blood-derived
germ-line DNA and matched micro-dissected tumor DNA
were investigated using 10 K SNP arrays. The characteris-
tics of these patients are shown in Table 1. The average sig-
nal detection rate was higher in germ-line DNA (99%)
than that in micro-dissected tumor DNA (79%). Based on
NCBI Build 35.1, we summarized characteristics of
11,555 SNPs and mapped them to chromosomes and
genes. We first generated a genotyping profile for each
patient based on a comparison of the germ-line DNA gen-
otypes to those from the matched micro-dissected tumor
DNA. The patients' LOH frequencies, shown in Table 1,
ranged from 19% to 95%, and averaged 29%. LOH in four
cases (SHE0832, SHE0864, SHE1264, and SHE1490) was
performed using DNA from micro-dissected adjacent nor-
mal tissue in addition to blood-derived germ-line DNA to
see if this affected results, but findings were very similar
with both of these two sources of DNA (Table 1).
The frequencies of LOH on each chromosomal arm are
shown in Table 2. Non-random LOH was observed on 10
chromosomal arms, including 17p (76%), 9p (72%), 9q
(72%), 13q (68%), 17q (66%), 4q (65%), 4p (60%), 3p
(58%), 15q (57%), and 5q (52%). Our previous micros-
atellite marker-based genome-wide LOH scan in 11 ESCC
patients with a positive family history of upper gastroin-
testinal cancer produced overall LOH frequencies that
were somewhat higher than the patients evaluated in the
present study [15]. We can not explain this between-study
LOH frequency variation, but there are several noteworthy
differences between the studies that likely influenced
LOH rates, including: (i) heterozygosity is higher for the
microsatellite compared to the SNP markers examined
(~75% versus ~30%); (ii) the total number of markers was
much higher in the SNP study than the microsatellite
study (11,000 versus 366); and (iii) over twice as many
cases were examined in the SNP study (26 versus 11).
Some results between studies differed (eg, LOH was ≥
50% on chromosome 15q in the SNP but not the micros-
atellite study; LOH was ≥ 50% on 8p, 8q, 11p, 11q and
18p in the microsatellite but not the SNP study). Despite
differences in study size, approach, and in some of the
results, consistently high LOH frequencies were reported
for nine chromosomal arms in both studies (ie, 3p, 4p,
4q, 5q, 9p, 9q, 13q, 17p, 17q). Both studies taken together
indicate that LOH on these nine chromosomal arms are
the major events associated with genome-wide instability
in ESCC in this high-risk Chinese population. These areas
are rich in known tumor suppressor genes and oncogenes,
including VHL on 3p; NPCA1 on 4p; KIT, GIST, and PDG-B
M
C
 
G
e
n
o
m
i
c
s
 
2
0
0
6
,
 
7
:
2
9
9
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
1
6
4
/
7
/
2
9
9
P
a
g
e
 
3
 
o
f
 
1
6
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 1: Demographic, risk factor, clinical characteristics, and LOH frequency of ESCC patients (N = 26)
No. ID Age/sex Tumor 
location
Tumor 
stage/grade
Metastasis FH of UGI 
cancer (Y/N)
Tobacco 
use (Y/N)
Alcohol 
use (Y/N)
Pickled 
vegetables (Y/N)
Survival 
status
Survival 
months
LOH*
 (blood DNA reference)
LOH* (normal 
esophagus reference)
1 SHE0043 72/M lower 3/II Y N Y N N deceased 29.6 0.951
2 SHE0133 55/M lower 1/III Y Y Y N N deceased 36.5 0.907
3 SHE0200 46/M middle 1/III Y Y Y Y Y deceased 45 0.875
4 SHE0204 51/M middle 2/III N Y Y N N alive 64.9 0.345
5 SHE0223 60/M middle 2/III N Y N N Y deceased 34.8 0.807
6 SHE0297 64/M middle 4/III Y Y Y Y N deceased 6.9 0.596
7 SHE0362 52/M middle 2/I Y Y Y Y Y alive 58.1 0.236
8 SHE0366 46/M lower 3/II Y N Y Y N deceased 26.2 0.849
9 SHE0633 63/M lower 3/III N Y Y N Y deceased 26.5 0.635
10 SHE0758 54/M lower 3/III N N Y N N deceased 6.6 0.267
11 SHE0782 49/F middle 2/II Y Y N N Y deceased 29.6 0.211
12 SHE0816 58/M upper 3/III N Y Y Y Y deceased 30.7 0.262
13 SHE0832 52/M middle 3/II N Y Y Y Y alive 42.5 0.215 0.219
14 SHE0848 62/F middle 3/II N N Y N Y alive 39.0 0.384
15 SHE0863 51/M upper 3/II N N Y Y Y alive 39.4 0.567
16 SHE0864 55/M middle 4/II Y N Y Y Y deceased 10.8 0.204 0.197
17 SHE0878 67/M lower 3/I N Y Y Y Y deceased 2.2 0.806
18 SHE0905 58/F middle 3/II N N N N Y alive 35.5 0.188
19 SHE0912 45/M middle 3/II Y N Y N Y deceased 31.2 0.747
20 SHE0921 64/M lower 3/III N Y Y Y Y deceased 13.2 0.246
21 SHE1255 61/M middle 2/II Y Y N Y Y deceased 20.0 0.567
22 SHE1264 68/M middle 3/II Y N Y Y N deceased 16.2 0.27 0.267
23 SHE1301 64/M middle 3/II Y Y N N Y alive 23.2 0.233
24 SHE1310 55/F middle 2/II Y N N N Y unknown - 0.593
25 SHE1408 63/M middle 3/II N N Y Y N deceased 23.3 0.224
26 SHE1490 52/M middle 3/II N N Y Y Y alive 20.0 0.3 0.287BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
Page 4 of 16
(page number not for citation purposes)
FRA on 4q; APC and MCC on 5q; CDKN2A and CDKN2B
on 9p; BRCA2 and Rb1 on 13q; TP53 on 17p; and BRCA1,
TOC, and NF1 on 17q.
LOH regions
When we used the conservative, traditional approach to
LOH in LOH/Model A, we detected 20 LOH regions
encompassing a total of 125 SNPs. As shown in Table 3,
these 20 LOH regions are located on eight chromosome
arms – 13q (four regions), 3p (two regions), 4q (three
regions), 9p (two regions), 9q (three regions), 17p (three
regions), 17q (two regions), and 4p (one region). The size
of these LOH regions ranged from 10 kb to 4.26 Mb (aver-
age 1.44 Mb); genes involved in these deletion regions are
shown in Table 3. Among the 125 SNPs in these 20 LOH
regions, 46 are located in genes (one in a coding exon, 39
in introns, and six in 3'- or 5'-UTRs), and 79 are located in
regions flanking genes (ie, within 1 kb). One SNP
(rs781852) is located in the coding region of gene ZZEF1
(Zinc finger, ZZ-type with EF-hand domain 1) on chro-
mosome 17p13.2. Allele A for this SNP encodes an amino
acid proline (Pro) and the allele B encodes amino acid
leucine (Leu). Eight of 10 heterozygous cases (Pro/Leu)
showed LOH (80%), including five cases that lost allele B
and three cases that lost allele A. The 46 SNPs that are
located within genes map to 32 genes and include four
SNPs in the introns of ZNF618, and two SNPs each in the
introns of ITPR1, FLJ14834, LHFP, ITGAE, MYH3 and
MYOCD. Some of these 20 deletion regions have been
previously identified by our lab and others [17,22]. How-
ever, the current study provides far greater precision in
locating LOH regions (10 kb-4.26 Mb as opposed to 10
cM, which corresponds to 5–10 Mb). As expected, using a
less conservative definition for LOH, LOH/Model B
detected more regions (and SNPs) than our approach in
LOH/Model A – 72 LOH regions containing 2,916 SNPs.
The distribution of deletion regions and details from this
model are shown in Table 4 and Additional Table 1 (in
additional file 1).
Our cLOH data in cLOH/Model A identified only three
significant cLOH regions. These included one on 13q12-
q13 and two on 13q13, and encompassed a total of 30
SNPs. The sizes of these cLOH regions are 1.9 Mb, 0.4 Mb,
and 0.2 Mb, respectively (average 0.83 Mb) (Table 5). The
less conservative cLOH/Model B highlighted 64 cLOH
regions with 2,128 SNPs; details are shown in Table 6 and
Additional Table 2 (in additional file 1).
Examples of the whole genome profiles for regions on
chromosome arms 9p/q, 13q, and 17p are shown in Fig-
ures 1, 2, 3.
Comparison of LOH and cLOH regions
Our conservative LOH/Model A detected 20 LOH regions
including 125 SNPs, but our conservative cLOH/Model A
detected only three LOH regions containing 30 SNPs. The
detection of only three LOH regions by cLOH/Model A is
not unexpected since identifying an LOH region in a sam-
ple requires the presence of multiple homozygous SNPs
Table 2: LOH distribution by chromosomal arm
Chr arm LOH in ESCC (n = 26) Chr arm LOH in ESCC (n = 26)
1p 0.282 (563/1998) 11p 0.393 (444/1130)
1q 0.211 (377/1787) 11q 0.372 (591/1590)
2p 0.301 (561/1861) 12p 0.259 (149/576)
2q 0.331 (782/2363) 12q 0.265 (496/1874)
3p 0.576 (955/1658) 13q 0.682 (1300/1907)
3q 0.287 (482/1677) 14q 0.461 (846/1836)
4p 0.602 (509/846) 15q 0.568 (845/1487)
4q 0.645 (1424/2208) 16p 0.285 (148/520)
5p 0.316 (286/906) 16q 0.338 (213/631)
5q 0.516 (1321/2560) 17p 0.755 (246/326)
6p 0.445 (545/1226) 17q 0.673 (450/669)
6q 0.417 (981/2351) 18p 0.409 (142/347)
7p 0.331 (398/1201) 18q 0.481 (513/1067)
7q 0.348 (539/1551) 19p 0.389 (58/149)
8p 0.433 (331/764) 19q 0.442 (184/416)
8q 0.313 (550/1759) 20p 0.318 (208/655)
9p 0.717 (867/1209) 20q 0.335 (178/532)
9q 0.715 (714/999) 21q 0.391 (339/866)
10p 0.367 (314/855) 22q 0.349 (157/450)
10q 0.366 (694/1897)
Average LOH = 0.425BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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Table 3: Deletion regions from the conservative "LOH/Model A"
Deletion 
region no.
Chr Cytoband(s) Start (Mb) End (Mb) Size (Mb) No. SNPs in each 
deletion region
Genes in the deletion regions*
1 3 3p26 4.34 5.26 0.92 5 SUMF1 MRPS10P2 LOC401048 ITPR1 BHLHB2 
LOC442073 ARL10C EDEM1
2 3 3p24-p22 31.02 33.39 2.37 5 LOC339897 LOC391524 SIMP OSBPL10 
LOC344787 KIAA0089 LOC402126 CKLFSF8 
CKLFSF7 KKLFSF6
LOC285260 DNCLI1 LOC391526 CNOT10 
LOC389101 LOC389102 LOC131405 CCR4 
GLB1CRTAP
KIAA0527 FBXL2 UBP1*
3 4 4p15.3 9.9 9.91 0.01 5 NA
4 4 4q13 72.58 74.06 1.48 6 SLC4A4 GC LOC441023 GPR74 ADAMTS3 
LOC391669 FLJ1305
5 4 4q22 86.78 88.62 1.84 7 ARHGAP24 MAPK10 PTPN13 SOAT LOC401142 
MGC26744 LOC260422 MLLT2 KLHL8 
GAPDL4
FAM13A1 LOC441028 SCDR9
6 4 4q22 90.72 94.98 4.26 6 SNCA MMRN1 MGC48628 TMSL3 
LOC389212 LOC133083 GRID2 BMPR1B
7 9 9p23 11.19 12.05 0.86 6 NA
8 9 9p21.3 26.02 27.53 1.51 6 LOC441390 C9orf82 PLAA LRRC19 CCDC2 TEK 
C9orf14 C9orf11 MOBKL2B IFNK
9 9 9q22.1 86.09 87.21 1.12 6 HBLD2 ZCCHC6 LOC392358 GAS1 LOC157956 
FLJ45537 KIAA1529 TMOD1 C9orf197
10 9 9q22.3 97.08 97.42 0.34 5 LOC389777 LOC286359 TDRD7
11 9 9q31.3 102.8 103.35 0.53 5 CYLC2 LOC340511 ZNF618
12 13 13q12.3-q13 30 31.2 1.2 13 C13orf22 ALOX5AP LOC387917 LOC401732 
LOC440132 FLJ14834 MGC40178 HSPH1 
B3GTL 13CDNA73
13 13 13q13.1-q13.3 32 34.89 2.89 7 PFAAP5 APRIN LOC122038 KL STARD13 RFC3 
NBEA DCNAMKL1
14 13 13q13.3 37.13 39.05 1.92 8 TRPC4 Ufm1 DKFZp686J0811 STOML3 
C13orf23 LOC387921 LOC390397 LHFP
15 13 13q22 75.3 76.82 1.52 8 KCTD12 BTF3L1 LOC341720 LOC390413 
DHX9P CLN5 FBXL3A MYCBP2
16 17 17p13- 0.86 4.32 3.46 5 ABR MRPL14P1 LOC390754 TUSC5 YWHAE 
CRK MYO1C SKIP PITPN MGC34680 SCARF1 
RILP
p13.2 PRPF8 MGC14376 FLJ33817 SERPINF2 
SERPINF1 SMYD4 RPA1 RTN4RL1 
DPH2L1OVCA2 HIC1 C17orf31
LOC440396 SRR FLJ10534 RUTBC1 MNT 
LOC284009 MGC3329 PAFAH1B1 KIAA0664 
GARNL OR1D4
OR1D2 OR1E3P OR1G1 OR1P1P OR1A2 
OR1A1OR1D3P OR3A1 LOC390756 OR3A2 
OR1R1P OR1E1
OR3A3 OR1E2 NYD-SP20 ASPA TRPV3 TRPV1 
CARKL CTNS TAX1BP3 MGC2963 P2RX5 GSG2
ITGAE HSA277841 CAMKK1 P2RX1P2RX1 
ATP2A3 ZZEF1 MGC32124 ANKFY1 UBE2G1 
MGC29671 LOC124976
17 17 17p12 9.68 10.8 1.12 6 GLP2R RCV1 GAS7 RPS27AP1 MYH13 MYH8 
MYH4 MYH1 MYH2 MYH3 SCO1 MDS006 
LOC388335
LOC400573
18 17 17p12 12.52 13.45 0.93 6 MYOCD KIAA0672 ELAC2 HS3ST3A1
19 17 17q22 51.95 52.2 0.25 5 NOG
20 17 17q24 67.83 68.01 0.18 5 LOC146795 LOC440462
Total no. SNPs 125
*SNPs in genes (exons, introns, or 3'- or 5'-UTRs) are shown in bold.BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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Table 4: Deletion regions from the less conservative "LOH/Model B"
Chr arm No. deletion regions 
in each chr arm
Cytoband(s) Total no. SNPs 
in each chr arm
2q 1 2q35 6
3p 6 3p26-p25 3p25-p24.3 3p24 3p24-p14 3p14-p13 3p13 293
4p 4 4p16-p15.3 4p15.3 4p15.1-p13 4p12-q12 150
4q 5 4q21 4q21.2-q22 4q22-q31.2 4q31.2-q34 4q34-q35 486
5q 8 5q11.2-q15 5q15 5q21 5q22 5q23 (2) 5q32-q34 5q34-q35 357
6p 5 6p24-p23 6p22.3 6p22.2-p21.2 6p21.2 6p11.2-q12 75
6q 1 6q15 21
8p 4 8p23.2 8p22(3) 32
9p/q 3 9p24.3 9p24.3-p22 9p22-q33 507
10p 1 10p12.1-p11.2 5
11p 1 11p15.2 6
11q 2 11q23 11q24 20
13q 4 13q12.2-q31.1 13q31.1 13q32.1 13q32.1-q34 391
14q 10 14q11.2-q12 14q12 (2) 14q21 (3) 14q23 (2) 14q23-q24.2 14q24.3 138
15q 10 15q11.2-q14 15q14 15q14-q15 15q15-q21.1 15q21.1 15q21.3-q23 15q25 (3) 15q25-q26.2 190
17p/q 1 17p13-q25 174
18q 4 18q21.1-q21.2 18q21.2 18q22 (2) 47
21q 1 21q22.1 10
22q 1 22q12.1-q12 8
Total no. 
deletion regions
72 Total no. SNPs 2916
Table 5: Deletion regions from the conservative "cLOH/Model A"
Deletion 
region no.
Cytoband Start (Mb) End (Mb) Size (Mb) No. SNPs in each 
deletion region
SNP list* Gene list
1 13q12-q13 27.4 29.3 1.9 15 rs720661 
rs748253 
rs952648 
rs2987346 
rs1414357 
rs2388092
LOC440129 CDX2 FLT3 PAN3
rs2388093 
rs2388094 
rs1986785 
rs719199 
rs1590501 
rs724946
FLT1 LOC341784 C13orf12 LOC283537
rs2388094 
rs1986785 
rs719199 
rs1590501 
rs724946 
rs1409504
CYP51P2 KIAA0774 SLC7A1
rs1409506 
rs1073230
2 13q13 29.6 30 0.4 7 rs1073229 
rs1570613 
rs1331697 
rs1831549
KATNAL1 PRDX2P1 UBCH7N2 HMGB1
rs1343946* 
rs1343945 
rs1854953
FLJ14834
3 13q13 30.3 30.5 0.2 8 rs2007622 
rs876540 
rs912603 
rs2056443 
rs13080
LOC387917 LOC401732 LOC440132
rs1409379 
rs1328950 
rs1328949
FLJ14834 MGC40178 B3GTL
Total no. SNPs 30
*Italicized SNPs are in genes; bolded SNPs are also found in the 20 deletion regions of the conservative LOH/Model A.BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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in a large genomic area and the chance for multiple
homozygous SNPs in more than 75% of the samples is
low. The three cLOH regions are all on chromosome
13q12-q13. Eleven SNPs were detected by both conserva-
tive LOH and cLOH models (LOH/Model A and cLOH/
Model A) (Tables 3 and 5). Five SNPs detected by the con-
servative cLOH/Model A are located in two genes,
FLJ14834 and B3GTL. Due to the relatively small number
of LOH regions defined by cLOH/Model A, as well as the
different definitions of LOH used in these two
approaches, it was not possible to compare the concord-
ance between these two methods.
Our less conservative LOH/Model B and cLOH/Model B
were identical except that LOH/Model B used the matched
normal controls while cLOH/Model B used pooled nor-
mal control samples. SNPs in the LOH regions from LOH/
Model B totaled 2,916; 2,128 SNPs were identified in the
cLOH regions from cLOH/Model B. The number of SNPs
common to both LOH and cLOH models (LOH/Model B
and cLOH/Model B) was 1,878, while a total of 1,038
SNPs appeared only in LOH/Model B, 250 SNPs were
found only in cLOH/Model B, and 7,834 showed reten-
tion in both models. Using LOH/Model B as a standard,
sensitivity/specificity for cLOH/Model B were 64% and
97%, respectively. The overall Pearson correlation coeffi-
cient between these two models was 0.69 (P < 0.0001).
Taken together, we detected more SNP loci in LOH/Model
B than cLOH/Model B, but concordance between the two
methods was generally good, suggesting that the use of
pooled normal control samples may be acceptable for
LOH studies.
CNA regions
Table 7 shows 15 regions with CNA losses that were
detected at P ≤ 10-6. These include regions on 1p, 3p, 4q,
5q, 9p, 10p, 11p, 11q, 13q, and 18q. One-hundred and
two SNPs were mapped within these regions (Table 4A).
Details of the involved SNPs and genes are shown in Addi-
tional Table 3 (in additional file 1). Table 8 shows the 36
regions where significant CNA gains were identified,
including eight on chromosomal arm 3q, seven on 8q,
three on 7p, two on 5q, two on 14q, and two on 22q
(Additional Table 4 in additional file 1). Examples of
whole genome profiles of CNA regions are shown for
chromosomes 3, 7, and 8 in Figures 4, 5, 6.
Comparisons between LOH and CNA
We obtain both cLOH and CNA data when we use the
pooled normal control sample reference in the CNAT soft-
ware. Thus we can ask the question of whether the cLOH
is associated with CNA. Our studies showed that among
2,128 SNPs identified in our less conservative cLOH/
Model B, only 45 (2%) showed CNA loss and just 14
(0.7%) showed CNA gain (Figure 7). This result suggests
that CNA accounts for small percent of LOH events in
ESCC. LOH in cancers is commonly caused by one of
three different mechanisms. The first and most common
cause of LOH is mitotic recombination [3]. This mecha-
nism doesn't change chromosome copy number, and was
responsible for 97% of the LOH observed in our study.
Deletion, the second cause of LOH, should result in copy
number loss, and occurred in approximately two percent
of LOH in our study. Finally, LOH can result from ampli-
fication of one chromosome, which should show copy
Table 6: Deletion regions from the less conservative "cLOH/Model B"
Chr arm No. regions in each chr arm Cytoband(s) Total no. SNPs in 
each chr arm
2q 2 2q34-q35 2q35 33
3p 7 3p26 (2) 3p26-p25 3p21.32-p2.2 182
4p 4 4p16.3-p15.3 4p15.3 4p12 4p12-q12 100
4q 14 4q13 (2) 4q13-4q22 4q26 4q27 4q27-q28 4q28 377
4q28-q32 4q32 4q32-q33 4q33-q34 4q34
5q 15 5q11.2 5q11.2-q12 5q12 5q13 5q13-q15 5q15 5q15-q21 386
5q21-q22 5q22 (2) 5q23.1 5q23.1-q23 5q32-q34 5q34-q35 5q35
8p 2 8p22 (2) 13
9p 5 9p24.3-p23 9p23-p21 9p21.3-p21.1 9p21-p13 9p13-q22 367
9q 2 9q22.2-q22.3 9q22.3-q33 147
13q 7 13q12.2-q14 13q14-q21.1 13q21.1-q21.33 365
13q21.33-q31.1 13q31.3-q32.1 13q32.1-q33 13q33
17p 2 17p13-p12 17p12-q21 96
17q 3 17q21-q22 17q22-q24 17q24 57
21q 1 21q22.2 5
Total no. 
deletion regions
64 Total no. SNPs 2128BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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number gain. This mechanism accounted for less than
one percent of LOH in our study. Although chromosomal
amplification occurs often, only occasionally do amplifi-
cation events result in LOH, which correspond to unbal-
anced amplification of one chromosome. However, some
studies have demonstrated concordance between LOH
and CNA. For example, Wong et al found LOH associated
with CNA gain at 6q12-13 in osteosarcoma [5], and Zhao
et al found a link between LOH and CNA gain at 1q22-
q24.1 and 1q42.13-43 in oral squamous cell carcinoma
[8]. These differences might reflect genuine differences
between tumor types, the lab analytic methods used, or
different operative mechanisms at work.
The genome-wide LOH and chromosome copy alteration
studies described in this paper can also be applied to
higher density SNP chips, such as Affymetrix 100 K and
500 K SNP chips. The increased SNP density will allow
even finer mapping of these genetic changes.
In summary, we performed a genome-wide study of LOH
and CNA in ESCC patients using the Affymetrix 10 K SNP
chip by comparing matched germ-line and tumor DNA.
Our approach allowed us to extensively map both LOH
and CNAs in ESCC systematically in a manner that has
not heretofore been done, and produced numerous
regions, genes, and SNPs that merit future exploration.
Chromosome 9 Figure 1
Chromosome 9. Each column in the picture represents an individual case and shows genotyping in germ-line DNA and 
matched micro-dissected tumor; LOH is shown in red, retention in blue, and homozygous or "no call" in grey. B indicates 
blood DNA and T indicates tumor DNA (from matched, micro-dissected sample). To the left of the picture, columns show 
(from left to right): microsatellite markers, cartoon of the chromosome, and SNPs examined in the 10 K SNP chip. To the right 
of the picture, red bars show deletion regions (as defined from our conservative "LOH/Model A"), blue bars show regions with 
CNA losses (from CNAT), and green bars show regions with CNA gains (from CNAT).BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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This report is the first comprehensive genome-wide anal-
ysis of chromosomal imbalance (LOH and CNA) in
ESCC, and the knowledge gained from this analysis will
enable the development of improved strategies to prevent,
diagnose, and treat ESCC patients in the future.
Conclusion
The Affymetrix 10 K SNP chip is a valid platform to inte-
grate analyses of loss of heterozygosity and copy number
alterations. The comprehensive knowledge gained from
this analysis will enable improved strategies to prevent,
diagnose, and treat esophageal squamous cell carcinoma.
Methods
Patient selection
This study was approved by the Institutional Review
Boards of the Shanxi Cancer Hospital and the US National
Cancer Institute. Patients diagnosed with ESCC between
1998 and 2000 in the Shanxi Cancer Hospital in Taiyuan,
Shanxi Province, People's Republic of China, and consid-
ered candidates for curative surgical resection were identi-
fied and recruited to participate in this study. None of the
patients had prior therapy and Shanxi was the ancestral
home for all. After obtaining informed consent, patients
were interviewed to obtain information on demographic,
clinical, and cancer lifestyle risk factors (smoking, alcohol
drinking, and detailed family history of cancer). All
patients were followed to ascertain survival status through
2003.
Biologic specimen collection and processing
Ten milliliters of venous blood was taken from each
patient prior to surgery and germ-line DNA was extracted
and purified using standard methods. Tumor and adja-
Chromosome 13 Figure 2
Chromosome 13. Each column in the picture represents an individual case and shows genotyping in germ-line DNA and 
matched micro-dissected tumor; LOH is shown in red, retention in blue, and homozygous or "no call" in grey. B indicates 
blood DNA and T indicates tumor DNA (from matched, micro-dissected sample). To the left of the picture, columns show 
(from left to right): microsatellite markers, cartoon of the chromosome, and SNPs examined in the 10 K SNP chip. To the right 
of the picture, red bars show deletion regions (as defined from our conservative "LOH/Model A"), blue bars show regions with 
CNA losses (from CNAT), and green bars show regions with CNA gains (from CNAT).BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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cent normal tissue obtained during surgery were either
fixed in ethanol and embedded in paraffin, or snap frozen
in liquid nitrogen and stored in a freezer at -80°C until
used. Slides were stained with H&E to distinguish tumor
from normal epithelium, and tumor cells were micro-dis-
sected under light microscopy using either laser capture
micro-dissection (LCM) (for paraffin-embedded samples)
or manual dissection (for frozen samples). All micro-dis-
sections were performed by a pathologist (NL) and a
trained post-doctoral fellow (HS). Extraction of LCM
DNA was previously described [17,23]. Extraction of man-
ually micro-dissected DNA followed the protocol from
the Puregene DNA Purification Tissue Kit (Cat Number D-
7000A, Gentra Systems, Inc., Minneapolis, MN 55441,
USA).
It is well known that using pure tumor DNA obtained by
micro-dissection is key to successfully detecting chromo-
somal changes such as LOH and CNA. However, the 10 K
chip requires amplification of DNA fragments up to 1 Kb,
a particularly challenging task. It is usually difficult to
obtain a high yield of DNA from alcohol- or formalin-
fixed tissues, especially when using micro-dissection. In
our study, the SNP call rates were much lower in micro-
dissected tumor DNA from alcohol-fixed tissue than from
frozen tissue (data not shown). Although the isolation of
tumor DNA from ground tissue using Trizol yielded
higher genotype call rates, we think that it is more impor-
tant to identify LOH and CNA regions than to simply
obtain higher genotype call rates. Thus, the best overall
genomic characterization results can be expected from the
use of micro-dissected frozen tissue.
Affymetrix GeneChip Mapping 10 K array
The 10 K SNP array provides comprehensive coverage of
the genome for genotyping studies. Each array contained
11,555 bi-allelic polymorphic SNPs randomly distributed
throughout the genome, except for the Y chromosome.
The median physical distance between SNPs is approxi-
mately 105 kb, and the mean distance between SNPs is
210 kb. The average heterozygosity for these SNPs is 0.37,
with an average minor allele frequency of 0.25. The algo-
rithm used to make genotype calls was previously
described by Affymetrix [24,25]. DNA samples were
assayed according to the protocol (GeneChip Mapping
Assay manual) supplied by Affymetrix, Inc. (Santa Clara,
CA) as previously described [25,26]. The 10 K SNP arrays
were scanned with the Affymetrix GeneChip Scanner
3000 using GeneChip Operating System 1.2 (GCOS)
(Affymetrix). Data files were generated automatically.
Genotype assignments (ie, calls) were made automatically
by GeneChip DNA Analysis Software 3.0 (GDAS)
(Affymetrix). The genetic map used in the analysis was
obtained from GeneChip Mapping 10 K library files: Map-
ping 10K_Xba131. "Signal Detection Rate" is the percent-
age of SNPs that passed the discrimination filter. "Call
Rate" is the percentage of SNPs called on the array. Geno-
type calls are defined as AA, AB, or BB; "no call" means the
Chromosome 17 Figure 3
Chromosome 17. Each column in the picture represents an individual case and shows genotyping in germ-line DNA and 
matched micro-dissected tumor; LOH is shown in red, retention in blue, and homozygous or "no call" in grey. B indicates 
blood DNA and T indicates tumor DNA (from matched, micro-dissected sample). To the left of the picture, columns show 
(from left to right): microsatellite markers, cartoon of the chromosome, and SNPs examined in the 10 K SNP chip. To the right 
of the picture, red bars show deletion regions (as defined from our conservative "LOH/Model A"), blue bars show regions with 
CNA losses (from CNAT), and green bars show regions with CNA gains (from CNAT).BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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Chromosome 3 Figure 4
Chromosome 3. Each column in the picture represents an individual case and shows genotyping in germ-line DNA and 
matched micro-dissected tumor; LOH is shown in red, retention in blue, and homozygous or "no call" in grey. B indicates 
blood DNA and T indicates tumor DNA (from matched, micro-dissected sample). To the left of the picture, columns show 
(from left to right): microsatellite markers, cartoon of the chromosome, and SNPs examined in the 10 K SNP chip. To the right 
of the picture, red bars show deletion regions (as defined from our conservative "LOH/Model A"), blue bars show regions with 
CNA losses (from CNAT), and green bars show regions with CNA gains (from CNAT).BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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SNP for that sample did not pass the discrimination filter
and was excluded from further evaluation in the present
study.
Data analysis
Since patient-matched normal DNA is not always availa-
ble as a reference for high-resolution allelotyping, we eval-
uated LOH using two different methods: first, we used
patient-matched normal DNA as the reference (the tradi-
tional approach); and second, we assessed whether it was
possible to instead use a pool of normal control samples
as the reference, as is done with the chromosome Copy
Number Analysis Tool 2.0 software (CNAT) from Affyme-
trix.
In the first method, LOH was defined in a traditional
manner as a change in genotyping call from heterozygos-
ity (AB) in the germ-line DNA, to homozygosity (AA or
BB) in the matched micro-dissected tumor DNA (all calls
from GDAS). In the second method, LOH was also
defined as a change in genotyping from "normal" to
tumor, however, "normal" here was defined based on
data already present in the Affymetrix CNAT software
from prior testing of 100 ethnically-diverse normal refer-
Chromosome 7 Figure 5
Chromosome 7. Each column in the picture represents an individual case and shows genotyping in germ-line DNA and 
matched micro-dissected tumor; LOH is shown in red, retention in blue, and homozygous or "no call" in grey. B indicates 
blood DNA and T indicates tumor DNA (from matched, micro-dissected sample). To the left of the picture, columns show 
(from left to right): microsatellite markers, cartoon of the chromosome, and SNPs examined in the 10 K SNP chip. To the right 
of the picture, red bars show deletion regions (as defined from our conservative "LOH/Model A"), blue bars show regions with 
CNA losses (from CNAT), and green bars show regions with CNA gains (from CNAT).BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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ence subjects [27]. LOH in the second method was based
on a comparison of a track of contiguous SNPs in tumor
to the analogous track of contiguous SNPs in the "nor-
mal" population DNA. Since the "normal" DNA here
includes not just one but 100 individuals, the state of
these SNPs (ie, whether they are heterozygous or
homozygous) was inferred statistically as a likelihood
estimation with confidence calculated from a binomial
distribution of the observed state of these SNPs in this
normal population. A contiguous run of homozygous
SNPs in tumor where these SNPs are heterozygous in the
"control" suggests LOH in the region spanning the SNPs.
Hence, no germ-line DNA data from cases was used for
this second analysis. We refer to this LOH as "cLOH" to
distinguish it from our more traditional analysis approach
using paired normal and tumor samples and to indicate
that it utilized a common control pool of normal DNA
generated by CNAT. The threshold for statistical signifi-
cance used in CNAT was P ≤ 10-6 as recommended by
Affymetrix [27].
We combined the LOH results from a cluster of SNPs in a
genetic locus to define a deletion region. We defined these
deletion regions in several ways to permit comparison
with the existing scientific literature as well as to make
comparisons within our own study using different refer-
Chromosome 8 Figure 6
Chromosome 8. Each column in the picture represents an individual case and shows genotyping in germ-line DNA and 
matched micro-dissected tumor; LOH is shown in red, retention in blue, and homozygous or "no call" in grey. B indicates 
blood DNA and T indicates tumor DNA (from matched, micro-dissected sample). To the left of the picture, columns show 
(from left to right): microsatellite markers, cartoon of the chromosome, and SNPs examined in the 10 K SNP chip. To the right 
of the picture, red bars show deletion regions (as defined from our conservative "LOH/Model A"), blue bars show regions with 
CNA losses (from CNAT), and green bars show regions with CNA gains (from CNAT).BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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ence groups as noted above. We first used a definition that
permitted comparisons with most of the existing pub-
lished literature. We constrained the SNPs we considered
here to require that: (i) SNPs have a call in ≥ 50% of the
normal DNA samples; (ii) there be a minimum of three
informative (heterozygous) normal samples; and (iii) the
SNPs be mappable to NCBI Build 35.1. Non-random
allelic loss was defined as LOH frequency ≥ 50% at a given
locus, while random allelic loss represented LOH fre-
quency <50% at a locus. Using these constraints for the
SNPs evaluated, we defined deletion regions very conserv-
atively by requiring that the deletion regions have five or
more contiguous SNPs which showed ≥ 75% LOH. Unin-
formative SNPs in the regions of LOH were excluded from
consideration in this analysis. Thus, a region of LOH sep-
arated from a second region of LOH by only uninforma-
tive SNPs would be combined into one large LOH region.
We labeled this conservative, traditional approach "LOH/
Model A".
The second approach we took (labeled "LOH/Model B")
was very similar to LOH/Model A in that we used the same
constraints on the SNPs noted above, but we were less
conservative in our requirement for the percent of the
deletion region which showed LOH – only ≥ 50% LOH
frequency (instead of ≥ 75%) among the SNPs was
required to be classified as a deletion region. To enable
comparability with data from the cLOH approach
Table 8: Regions with copy number alteration gain from CNAT
Chr arm No. CNA gain regions in 
each chr arm
Cytoband(s) Total no. SNPs in 
each chr arm
1p 1 1p36.13 5
1q 1 1q21.3-1q21 8
2p 1 2p14 6
2q 2 2q11.2 2q21 15
3q 8 3q21-q22 3q22-q23 3q23(2) 3q24 3q26.1 3q27 3q28 69
5p 2 5p15.2 (2) 14
5q 1 5q11.2 5
6p 1 6p25.3-p24 8
7p 3 7p14 (2) 7p12 24
7q 1 7q11.21-q11.22 5
8q 7 8q24.2 (2) 8q24.1 (3) 8q22 8q11.2 66
9q 1 9q31-q31.3 7
14q 2 14q21-q22 14q22-q23 16
17p 1 17p13.1-p13.2 7
18p 1 18p11.31 8
20p 1 20p11.1-q11.1 13
22q 2 22q12.1 22q13.1 11
Total no. gain regions 36 Total no. SNPs 287
Table 7: Regions with copy number alteration loss from CNAT
Chr arm No. CNA loss regions in each chr arm Cytoband(s) Total no. SNPs in each chr arm
1p 1 1p13.3 5
3p 3 3p24 3p25-p24.3 3p25 19
4q 1 4q28 5
5q 2 5q14-q15 5q33 23
9p 1 9p21.3 8
10p 1 10p12-p12.1 7
11p 1 11p15.5 5
11q 2 11q21 (2) 10
13q 2 13q12.2-q12 13q14 14
18q 1 18q22 6
Total no. loss regions 15 Total no. SNPs 102BMC Genomics 2006, 7:299 http://www.biomedcentral.com/1471-2164/7/299
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described above, we also adopted different guidance
regarding how we treated homozygous SNPs in these
putative LOH regions defined by the traditional approach.
In CNAT, a contiguous track of homozygous SNPs are
required to designate a region as having LOH. When a
homozygous SNP is located between two SNPs where one
or both of the adjacent SNPs showed retention of hetero-
zygosity, the homozygous SNP was considered retained.
Otherwise, it was treated as LOH.
We also developed two models using exclusively data
from the cLOH approach with the CNAT-generated
pooled controls. The first used the conservative definition
described above for LOH/Model A of a ≥ 75% LOH
requirement to declare a deletion region, and also treated
homozygous SNPs in deletion regions in accord with the
CNAT algorithm described above; we termed this "cLOH/
Model A". Although the level of LOH required is the same
for LOH/Model A and cLOH/Model A, direct comparisons
between them are not possible because of the different
algorithms used to treat uninformative SNPs in deletion
regions. The second approached loosened the LOH
requirement to ≥ 50% to declare a deletion region (as with
LOH/Model B above), also used the CNAT algorithm for
homozygous SNP calls in deletion regions, and was
termed "cLOH/Model B".
Individual SNP copy numbers and chromosomal regions
with gains or losses were also determined by evaluation
with CNAT based on the SNP hybridization signal inten-
sity data from the experimental sample relative to inten-
sity distributions derived from the previously described
reference set containing over 100 normal individuals [27].
P-values were log10-transformed and plotted along the
corresponding chromosome; values were considered sig-
nificant at P ≤ 10-6.
We further defined CNA-gain regions as regions where
five or more contiguous SNPs showed copy number gain
in at least 50% of cases, and the P-value for the difference
from the reference was ≤ 10-6. Similarly, CNA-loss regions
were defined as regions where five or more contiguous
SNPs showed copy number loss in at least 50% of cases,
and the P-value for the difference from the reference was
≤ 10-6.
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